Abstract
Background
Recurrence and metastasis represent the primary causes of therapeutic failure in head and neck squamous cell carcinoma (HNSCC). However, the underlying molecular mechanisms driving these processes remain incompletely elucidated.
Methods
WNK1 (with-no-lysine kinase 1) expression in both normal and HNSCC tissues was analyzed using the TCGA, TIMER2.0 and Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets, and further validated in HNSCC cell lines by Western blot. Cell Counting Kit-8 (CCK-8), colony formation, Transwell, and orthotopic xenograft assays were conducted to assess the biological role of WNK1 in HNSCC proliferation and metastasis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) -based quantitative proteomics and post-translational modification profiling were performed to explore the underlying molecular mechanisms.
Results
WNK1 overexpression was significantly elevated in HNSCC tissues and cell lines and was correlated with reduced overall survival. WNK1 knockdown suppressed tumor growth and metastasis both in vivo and in vitro. Proteomic and phosphoproteomic profiling of WNK1-driven alterations identified critical signaling pathways closely associated with tumor malignancy. Specifically, WNK1 promotes NF-κB activation through RELA (p65) phosphorylation and nuclear accumulation, resulting in the upregulation of pro-tumorigenic effectors.
Conclusions
Elevated WNK1 drives invasive progression and distant metastasis in HNSCC through NF-κB-dependent transcriptional reprogramming, highlighting its potential as a novel therapeutic target for HNSCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
2 Southern Medical University, The First School of Clinical Medicine, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)




